Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.

By PA Marks, V. Richon, R. Rifkind. Journal of the National Cancer Institute, 2000

1,225 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents (2015, background): “The balance between acetylation and deacetylation of histones or the reverse activities of HATs and HDACs regulate gene expression through chromatin modifications [4,5].”
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells (2001, background): “Several structurally diverse HDAC inhibitors have been identi®ed and their activity in transformed cells in vitro renders them prime candidates for cancer therapy (Marks et al., 2000; KraÈmer et al., 2001).”
Histone deacetylases and cancer: causes and therapies (2001, background): “Various chemical agents can induce these processes in transformed cell”
DNA methylation and gene silencing in cancer (2005, background): “A variety of HDAC inhibitors have been shown to inhibit histone deacetylation in human tumor cells, leading to accumulation of acetylated histone proteins”